RICHTER logo

Gedeon Richter PLC Stock Price

BUSE:RICHTER Community·Ft2.1t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 24 Fair Values set on narratives written by author

RICHTER Share Price Performance

Ft11,760.00
1110.00 (10.42%)
Ft15,095.00
Fair Value
Ft11,760.00
1110.00 (10.42%)
22.1% undervalued intrinsic discount
Ft15,095.00
Fair Value
Price Ft11,760.00
AnalystHighTarget Ft15,095.00
AnalystConsensusTarget Ft11,949.38
AnalystLowTarget Ft9,435.00

RICHTER Community Narratives

AnalystHighTarget·
Fair Value Ft15.1k 22.1% undervalued intrinsic discount

Women's Health And Biosimilars Will Drive Stronger Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value Ft11.95k 1.6% undervalued intrinsic discount

Women’s Health Tailwinds And CNS Pipeline Will Drive Long-Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value Ft9.44k 24.6% overvalued intrinsic discount

Women’s Healthcare Reliance And CDMO Risks Will Pressure Future Margins And Earnings

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Ft15.1k
22.1% undervalued intrinsic discount
Revenue
8.39% p.a.
Profit Margin
28.07%
Future PE
11.71x
Price in 2029
Ft21.11k
Ft11.95k
1.6% undervalued intrinsic discount
Revenue
7.91% p.a.
Profit Margin
28.99%
Future PE
9.42x
Price in 2028
Ft16.74k

Trending Discussion

Updated Narratives

RICHTER logo

Women’s Healthcare Reliance And CDMO Risks Will Pressure Future Margins And Earnings

Fair Value: Ft9.44k 24.6% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RICHTER logo

Women's Health And Biosimilars Will Drive Stronger Long Term Prospects

Fair Value: Ft15.1k 22.1% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RICHTER logo

Women’s Health Tailwinds And CNS Pipeline Will Drive Long-Term Earnings Power

Fair Value: Ft11.95k 1.6% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

1 Risk
2 Rewards

Gedeon Richter PLC Key Details

Ft929.0b

Revenue

Ft288.1b

Cost of Revenue

Ft640.9b

Gross Profit

Ft408.6b

Other Expenses

Ft232.3b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 30, 2026
1.27k
68.99%
25.01%
5.5%
View Full Analysis

About RICHTER

Founded
1901
Employees
10943
CEO
Gabor Orban
WebsiteView website
www.gedeonrichter.com

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, ‘FMC2’, for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.

Gedeon Richter PLC Competitors